Skip to main content
Premium Trial:

Request an Annual Quote

GenomOncology, Congenica Team up to Develop Precision Oncology Dx Platform

NEW YORK – GenomOncology and Congenica said Thursday that they are jointly developing a new diagnostic software platform to support precision oncology that relies on existing technology from both companies.

Through their new collaboration, the companies will develop the technology on the GenomOncology Precision Oncology Platform, then combine it with a new, automated data analysis application from Congenica to improve the usability and scalability of genomic data to produce clinical decision support for individualized cancer therapies.

The firms said they would seek CE-IVD marking in the European Union for their joint offering. Congenica already has a CE-IVD mark for its genomic data analysis and clinical decision support technology.

"Our partnership with Congenica enables us to expand opportunities for precision oncology care at the global level," Brad Wertz, CEO of Cleveland-based GenomOncology, said in a statement. "The extensive information available within the GenomOncology Precision Oncology Platform, combined with the capabilities of the Congenica Clinical Decision Support Platform, will give clinicians and researchers the knowledge needed to provide their patients with the most appropriate care opportunities."

The deal also represents the extension of Congenica's clinical decision support platform into oncology, according to Alistair Johnson, chief professional services officer for the Hinxton, UK-based company.

"Our novel product offers a fully automated, future-proof, end-to-end solution that unlocks the full potential of next-generation sequencing in the clinical oncology space," Johnson said.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.